Antimicrobial Dosing & Renal Clearance

Pathogen-Directed Selection, Kinetic GFR & Dialysis
⚙ Three-Phase Dosing: Loading doses are given at full strength regardless of renal function. Maintenance adjustments begin after 48h. Protocols reflect ICMR AMR guidelines where applicable.

1. Patient Characteristics

2. Renal Clearance Status

3. Antimicrobial Selection

Renal Replacement Therapy Reference: Select an antimicrobial and dialysis modality to review post-dialysis supplemental dosing recommendations and general clearance characteristics.

☤ Dialysis Clearance Database

⚒ Indian Antimicrobial Resistance (AMR) Context

The Indian Council of Medical Research (ICMR) AMRSN reports highly prevalent resistance patterns in tertiary care centers. Empirical therapy in Indian ICUs must account for:

  • Enterobacteriaceae: Exceptionally high rates of ESBL producers (>70%). Routine use of Ceftriaxone for hospital-acquired Gram-negatives is discouraged.
  • Carbapenem-Resistant Enterobacteriaceae (CRE): Driven primarily by NDM and OXA-48-like carbapenemases. High-dose Meropenem (if MIC is borderline) or polymyxin-based combinations are frequently required.
  • Acinetobacter baumannii: Often pan-drug resistant (PDR). High-dose Ampicillin-Sulbactam or Colistin forms the backbone of therapy.

The Critical Role of Kinetic GFR in AKI

Traditional equations (Cockcroft-Gault, CKD-EPI) assume a steady state of serum creatinine. In acute critical illness, this assumption is dangerously flawed.

⚠ The Clinical Pitfall
Serum creatinine lags behind actual glomerular filtration by 24 to 48 hours. If a patient's kidneys completely fail, creatinine only rises roughly 1.0 - 1.5 mg/dL per day. A calculator reading 1.8 mg/dL on Day 1 of AKI might suggest a CrCl of 40 mL/min, leading to massive antibiotic overdosing. Kinetic GFR corrects for this rate of change by calculating the appearance rate minus the volume of distribution shift.

Pharmacokinetic Principles of Antimicrobials

Killing Profile Target Metric Clinical Strategy
Time-Dependent
(Beta-lactams, Cephalosporins, Carbapenems)		 Time > MIC Frequent dosing, or extended/continuous infusions to maintain serum levels above the MIC. Crucial for high-MIC organisms in India.
Concentration-Dependent
(Aminoglycosides, Fluoroquinolones)		 Cmax / MIC Large, infrequent doses (e.g., Once-Daily Amikacin) to achieve a massive peak concentration, followed by a drug-free period to minimise toxicity.
Exposure-Dependent
(Vancomycin)		 AUC / MIC Maximise total area under the curve over 24h. TDM targeting AUC/MIC of 400-600 is mandatory to prevent nephrotoxicity.
Abbreviations: CG (Cockcroft-Gault) · CrCl (Creatinine Clearance) · AKI (Acute Kidney Injury) · IBW (Ideal Body Weight) · HD (Haemodialysis) · CRRT (Continuous Renal Replacement Therapy) · MIU (Million International Units) · CMS (Colistimethate Sodium) · ICMR (Indian Council of Medical Research) · ESBL (Extended-Spectrum Beta-Lactamases) · MIC (Minimum Inhibitory Concentration) · AUC (Area Under the Curve)
Algorithm References & Evidence Base
  1. ICMR Antimicrobial Resistance Surveillance Network (AMRSN) Annual Reports.
  2. The Sanford Guide to Antimicrobial Therapy (latest edition updates).
  3. Chen S. Retooling the Creatinine Clearance Equation to Estimate Kinetic GFR... J Am Soc Nephrol. 2013;24(5):877-888.
  4. Rybak MJ et al. Therapeutic monitoring of vancomycin for serious MRSA infections... Am J Health Syst Pharm. 2020;77(11):835-864.
  5. Tsuji BT et al. International Consensus Guidelines for the Optimal Use of the Polymyxins. Pharmacotherapy. 2019;39(1):10-39.
How to Cite This Tool

AMA Style:
Umakanth S. Antimicrobial Dosing & Renal Clearance Pathway. MEDiscuss. Published 2026. Accessed .

Vancouver Style:
Umakanth S. Antimicrobial Dosing & Renal Clearance Pathway [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:

⚠ Disclaimer: This decision-support system is intended for healthcare professionals. It does not substitute clinical judgment. These algorithms are evidence-based, but medical knowledge evolves continuously. The treating physician retains absolute responsibility for all diagnostic, dosing, and therapeutic decisions. Always verify outputs against current institutional protocols and individual patient contexts.
© 2026 MEDiscuss.org. All rights reserved. This CDSS Module was conceptualised, designed and developed by
Dr. Shashikiran Umakanth.Provided free of charge for clinical use. Unauthorised reproduction or redistribution is strictly prohibited.
Related Clinical Tools
Comprehensive Renal StagingWarfarin Titration PathwayDiabetes Management Pathway
Back to All Medical Calculators & Pathways